Paliperidone was initially approved by the United States Food and Drug Administration (FDA) on December 19, 2006. 

Paliperidone is used primarily to treat schizophrenia, a complex mental disorder characterized by disrupted thoughts, emotions, and behaviors. It is also employed in managing schizoaffective disorder, which combines features of schizophrenia and mood disorders. By influencing neurotransmitter activity in the brain, this medication helps alleviate symptoms like hallucinations, delusions, and mood disturbances, enhancing the overall quality of life for individuals facing these challenging conditions.

Paliperidone is administered through oral tablets or as an extended-release injection. The oral tablets are typically taken by mouth once daily, with or without food. The extended-release injection is administered by a healthcare professional as a monthly injection, gradually releasing the medication over time. The choice of administration route depends on the individual's condition, treatment plan, and the healthcare provider's recommendations.

Paliperidone may lead to a range of common and serious side effects. Common side effects could encompass drowsiness, dizziness, weight gain, increased heart rate, dry mouth, and constipation. More serious side effects might involve extrapyramidal symptoms, neuroleptic malignant syndrome, tardive dyskinesia, cardiovascular effects, metabolic changes, blood disorders, and even seizures. While these side effects can vary in intensity and occurrence, it's crucial to promptly communicate any concerns or unusual symptoms with a healthcare provider for appropriate guidance and management.

Paliperidone may increase the risk of cardiovascular events. Its use may be associated with an increased risk of cerebrovascular events, including stroke, especially in elderly patients with dementia-related psychosis. This medication can cause movement disorders like dystonia, akathisia, and Parkinsonism. These symptoms may be more pronounced in susceptible individuals.  Long-term use of this medication can lead to tardive dyskinesia, a potentially irreversible condition characterized by involuntary movements, particularly of the face and tongue. Neuroleptic malignant syndrome (NMS), a rare but potentially fatal reaction, can occur with its use. Symptoms include high fever, muscle rigidity, confusion, and autonomic dysregulation. This medication may lead to weight gain, increased blood sugar levels, and lipid abnormalities,

When using paliperidone, take precautions to address potential cardiovascular risks, cerebrovascular events, and metabolic changes, particularly in elderly patients with dementia. Monitor for extrapyramidal symptoms and tardive dyskinesia, and be aware of the rare but serious possibility of neuroleptic malignant syndrome. Regularly assess for hematologic effects and hyperprolactinemia, and take measures to prevent seizures and manage heat sensitivity. Gradual dose reduction is essential to avoid withdrawal symptoms. Exercise caution with driving and activities requiring alertness. Consider pregnancy and breastfeeding implications, and engage in an open dialogue with your healthcare provider about your medical history, concerns, and any changes in your condition.

When using Paliperidone, important precautions include avoiding it in case of hypersensitivity exercising caution if you have cardiovascular or cerebrovascular conditions, epilepsy, metabolic disorders, or a history of neuroleptic malignant syndrome (NMS). Regular monitoring of blood glucose, potential QT interval prolongation, and neutropenia is crucial. Beware of orthostatic hypotension, and report mood changes or suicidal thoughts. Gradual discontinuation is advised, and cognitive-motor impairment may occur. Hyperprolactinemia, heat exposure, and effects on the elderly and pediatric populations should be considered. Genetic factors may impact metabolism. Use caution with alcohol, driving, and operating machinery. Communication with your healthcare provider is key to ensuring the safe and effective use of this medication.

1. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of psychotics and mania, 12th edition, 2011, 428.
2. Janssen-Cilag International NV, Electronic medicines compendium (emc), [Revised on 06 Oct 2021] [ Accessed on 9th August 2023], https://www.medicines.org.uk/emc/product/6816/smpc#gref
3. Janssen Pharmaceuticals Inc, US Food and Drug Administration, [Revised on 06/2017] [ Accessed on 9th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022264s023lbl.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.